



*Targeted Genes and Methodology Details  
for Hemiplegic Migraine With or Without  
Epilepsy Gene Panel*

Next-generation sequencing (NGS) and/or Sanger sequencing is performed to test for the presence of variants in coding regions and intron/exon boundaries of the genes analyzed. NGS and/or a polymerase chain reaction (PCR)-based quantitative method is performed to test for the presence of deletions and duplications in the genes analyzed. Confirmation of select reportable variants may be performed by alternate methodologies based on internal laboratory criteria.

Genomic Build: GRCh37 (hg19) unless otherwise specified

<b>Gene</b>	<b>Reference Transcript<sup>a</sup></b>
<i>ATP1A2</i>	NM_000702.4
<i>ATP1A3</i>	NM_152296.5
<i>CACNA1A</i>	NM_001127221.1
<i>COL4A1</i>	NM_001845.6
<i>NOTCH3</i>	NM_000435.3

<b>Gene</b>	<b>Reference Transcript<sup>a</sup></b>
<i>POLG</i>	NM_002693.2
<i>PRRT2</i>	NM_145239.3
<i>SCN1A</i>	NM_001165963.3
<i>SLC2A1</i>	NM_006516.3

<sup>a</sup> Reference transcript numbers may be updated due to transcript re-versioning. Always refer to the final patient report for gene transcript information referenced at the time of testing.

To verify if a specific region/exon/variant is covered by this assay, contact a laboratory genetic counselor at 800-533-1710.